Inovalon Holdings, Inc. (INOV) EPS Estimated At $0.03

April 26, 2018 - By Lynda A. Deweese

Inovalon Holdings, Inc. (NASDAQ:INOV) Logo

Analysts expect Inovalon Holdings, Inc. (NASDAQ:INOV) to report $0.03 EPS on May, 2.They anticipate $0.02 EPS change or 40.00 % from last quarter’s $0.05 EPS. INOV’s profit would be $4.33M giving it 89.17 P/E if the $0.03 EPS is correct. After having $0.04 EPS previously, Inovalon Holdings, Inc.’s analysts see -25.00 % EPS growth. It closed at $10.7 lastly. It is down 14.88% since April 26, 2017 and is downtrending. It has underperformed by 26.43% the S&P500.

Inovalon Holdings, Inc. (NASDAQ:INOV) Ratings Coverage

Among 3 analysts covering Inovalon Holdings (NASDAQ:INOV), 0 have Buy rating, 2 Sell and 1 Hold. Therefore 0 are positive. Inovalon Holdings had 3 analyst reports since February 21, 2018 according to SRatingsIntel. The company was downgraded on Wednesday, March 14 by Morgan Stanley. Wells Fargo maintained the shares of INOV in report on Wednesday, February 21 with “Market Perform” rating. Piper Jaffray maintained Inovalon Holdings, Inc. (NASDAQ:INOV) on Wednesday, February 21 with “Sell” rating.

Inovalon Holdings, Inc., a technology company, provides cloud platforms empowering a data-driven transformation from volume to value models throughout the healthcare industry. The company has market cap of $1.55 billion. The firm through, large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and industry-leading subject matter expertise, enables the assessment and improvement of clinical and quality outcomes, and financial performance across the healthcare ecosystem. It has a 44.96 P/E ratio. It serves health plans and well-known provider organizations, as well as pharmaceutical, medical device, and diagnostics companies.

Inovalon Holdings, Inc. (NASDAQ:INOV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.